Sanaria is a biotechnology company developing vaccines protective against malaria. Sanaria’s vaccines have proven highly protective against Plasmodium falciparum infection in humans. Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Inc.'s blog
ROCKVILLE, MD, USA - June 8, 2021 - The PfSPZ malaria vaccines of Sanaria Inc. are unique in vaccine development as they are composed of weakened (attenuated) forms of the live parasite cells that cause malaria. These parasite cells are called eukaryotic cells and there are no vaccines against any infectious disease composed of such cells. Furthermore, there are no licensed vaccines against any infectious disease caused by a eukaryotic pathogen.
Watch below the recording of the MasterClass "The Enduring Search for Malaria Vaccines" with Sanaria's Chief Executive and Scientific Officer Prof Stephen Hoffman.
Ifakara MasterClasses in Public Health Research & Practice. Episode XXV: Thursday, June 3rd 2021.